The RAPS store will be under maintenance Saturday, 29 February between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > 2019 > 3 > EMA’s CHMP Recommends Gene Therapy With Record Review Time

EMA’s CHMP Recommends Gene Therapy With Record Review Time

Posted 29 March 2019 | By Zachary Brennan 

EMA’s CHMP Recommends Gene Therapy With Record Review Time

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday recommended a conditional marketing authorization for Bluebird Bio’s gene therapy Zynteglo (Autologous CD34+ cells encoding βA-T87Q-globin gene).

Zyntelgo addresses the underlying genetic cause of transfusion-dependent beta-thalassemia, a rare inherited blood condition that causes severe anemia. Zynteglo is intended for patients 12 years and older who need regular blood transfusions to manage their disease and do not have a matching donor for a stem cell transplant.

“In the two main studies to demonstrate the effects of Zynteglo it was shown that the majority of patients who do not have a β0/β0 genotype treated with Zynteglo no longer needed regular blood transfusions. The most common side effects were thrombocytopenia (low blood platelet count), abdominal pain, non-cardiac chest pain, pain in the extremities, dyspnoea and hot flush,” EMA said.

The gene therapy was granted an accelerated assessment and was reviewed in just 150 days, cutting as much as two months off the time a typical application takes to make it through the centralized procedure. EMA said it was “the fastest review time for an ATMP to date.”

The conditional aspect of the recommended authorization is because the company submitted less complete data than normally expected, EMA said, which is what happens when the agency deems a medicine’s immediate availability to patients outweighs the risk of not having more data.

And since Zynteglo addresses an unmet medical need, the agency said it benefited from the support of its PRIME scheme and Adaptive Pathways program, which provide for early and enhanced dialogue between the agency and drug developers. Zynteglo was also granted an orphan designation in 2013.

“As always at time of approval, EMA's committee for orphan medicines (COMP) will review the orphan designation to determine whether the information available to date allows maintaining Zynteglo’s orphan status and granting this medicine ten years of market exclusivity,” EMA said.

Bluebird said it’s the company’s first gene therapy submitted for regulatory approval, and a final decision by the European Commission is anticipated in the second quarter of 2019.

Last September, EMA’s CHMP recommended approval of another gene therapy, Spark Therapeutics’ Luxturna (voretigene neparvovec), for the treatment of a rare genetic disorder that causes vision loss and usually leads to blindness.

And regulators expect more gene and cell therapies are coming.

By 2020, FDA said it expects to be receiving upward of 200 INDs for cell and gene therapies each year, adding to the 800 active INDs for such products already filed with the agency. By 2025, FDA predicts the agency will be approving between 10 and 20 cell and gene therapy products annually.

EMA Guidelines on Gene Therapy

Regulatory Focus newsletters

All the biggest regulatory news and happenings.